Skip to main content
. 2020 Feb 18;54(5):1112–1115. doi: 10.1007/s43441-020-00131-5

Figure 2.

Figure 2.

Comparing Time to Progression (Treatment Discontinuation) in RWD and RCT for Patients with Advanced Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Data sources include IQVIA, COTA, Flatiron, Kaiser Permanente Cancer Research Network, Mayo Clinic/Optum Labs, and The University of Iowa PCORnet.